Is Autologous Hematopoietic Stem Cell Transplant Better Than High-Efficacy Disease-Modifying Therapies for Relapsing Multiple Sclerosis?
JAMA Neurology · 2023
DOI: 10.1001/jamaneurol.2023.0467 ↗Kurz gefasst
Editorial in der Zeitschrift JAMA Neurology, 2023. Verfasst von Jeffrey A Cohen und 1 weiteren Autor:innen. Beteiligte Einrichtung: Mellen Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio. Hauptthemen laut MEDLINE: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Mellen Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio.
- Department of Neurology, Washington University, St Louis, Missouri.
Zitieren
APA
Cohen, J. A., & Cross, A. H. (2023). Is Autologous Hematopoietic Stem Cell Transplant Better Than High-Efficacy Disease-Modifying Therapies for Relapsing Multiple Sclerosis?. JAMA Neurology. https://doi.org/10.1001/jamaneurol.2023.0467
Vancouver
Cohen JA, Cross AH. Is Autologous Hematopoietic Stem Cell Transplant Better Than High-Efficacy Disease-Modifying Therapies for Relapsing Multiple Sclerosis?. JAMA Neurology. 2023. doi:10.1001/jamaneurol.2023.0467
BibTeX
@article{Cohen2023,
author = {Cohen, Jeffrey A and Cross, Anne H},
title = {Is Autologous Hematopoietic Stem Cell Transplant Better Than High-Efficacy Disease-Modifying Therapies for Relapsing Multiple Sclerosis?},
journal = {JAMA Neurology},
year = {2023},
doi = {10.1001/jamaneurol.2023.0467}
}
EUVIMED